| pubmed-article:7872957 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0032176 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0031667 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0076552 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0040018 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C1948023 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0678640 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0597484 | lld:lifeskim |
| pubmed-article:7872957 | lifeskim:mentions | umls-concept:C0290523 | lld:lifeskim |
| pubmed-article:7872957 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:7872957 | pubmed:dateCreated | 1995-3-30 | lld:pubmed |
| pubmed-article:7872957 | pubmed:abstractText | A thrombin receptor has been described that is activated by thrombin cleavage generating a new N-terminus. The newly exposed SFLLR-containing "tethered-ligand" then activates the receptor. In these studies, we used 3-mercapto-propionyl-Phe-Cha-Cha-Arg-Lys-Pro-Asn- Asp-Lys-amide (Mpapeptide) as a thrombin receptor antagonist. This compound was capable of preventing both thrombin- and SFLLR-peptide-induced platelet aggregation with little effect on collagen-induced platelet aggregation. It also prevented thrombin- and SFLLRNP-induced calcium mobilization with little effect on thromboxane receptor-activated platelet Ca2+ mobilization. Platelet membrane GTPase could be activated by peptides that activated the thrombin receptor, and the thrombin receptor antagonist also prevented receptor-stimulated GTPase activity. Platelet phospholipase A2 (PLA2) activity (measured as the release of radiolabeled arachidonic acid) and Na+/H+ exchange activation were stimulated by alpha-thrombin and by SFLLR-containing peptides. Activation of both processes with low concentrations of thrombin required thrombin's anion-binding exosite, as they were not activated by similar concentrations of gamma-thrombin, and the alpha- and zeta-thrombin activation was blocked by peptides mimicking the C-terminal region of hirudin. Stimulation of PLA2 and Na+/H+ exchange by both thrombin and SFLLR-containing peptides was inhibited by the thrombin receptor antagonist Mpa-peptide. These results support the hypothesis that thrombin stimulation of PLA2 activity and Na+/H+ exchange occurs via activation of the thrombin tethered-ligand receptor. Moreover, these data are consistent with the tethered-ligand receptor mediating most actions elicited by low concentrations of alpha-thrombin involved in human platelet activation. | lld:pubmed |
| pubmed-article:7872957 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7872957 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7872957 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7872957 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:7872957 | pubmed:issn | 0006-2952 | lld:pubmed |
| pubmed-article:7872957 | pubmed:author | pubmed-author:FentonJ... | lld:pubmed |
| pubmed-article:7872957 | pubmed:author | pubmed-author:GoldenbergHH | lld:pubmed |
| pubmed-article:7872957 | pubmed:author | pubmed-author:MichelI MIM | lld:pubmed |
| pubmed-article:7872957 | pubmed:author | pubmed-author:NatarajanSS | lld:pubmed |
| pubmed-article:7872957 | pubmed:author | pubmed-author:SeilerS MSM | lld:pubmed |
| pubmed-article:7872957 | pubmed:author | pubmed-author:PelusoMM | lld:pubmed |
| pubmed-article:7872957 | pubmed:author | pubmed-author:RiexingerDD | lld:pubmed |
| pubmed-article:7872957 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7872957 | pubmed:day | 14 | lld:pubmed |
| pubmed-article:7872957 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:7872957 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7872957 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7872957 | pubmed:pagination | 519-28 | lld:pubmed |
| pubmed-article:7872957 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:meshHeading | pubmed-meshheading:7872957-... | lld:pubmed |
| pubmed-article:7872957 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7872957 | pubmed:articleTitle | Inhibition of thrombin and SFLLR-peptide stimulation of platelet aggregation, phospholipase A2 and Na+/H+ exchange by a thrombin receptor antagonist. | lld:pubmed |
| pubmed-article:7872957 | pubmed:affiliation | Department of Cardiovascular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543. | lld:pubmed |
| pubmed-article:7872957 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7872957 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7872957 | lld:pubmed |
